Stocks Health care MRNA
NASDAQ · Health careModerna, Inc. (MRNA)
Moderna, Inc. brought in $2.2B of revenue over the twelve months to June 30, 2026, down 27.6% from a year earlier. It posted a net loss of $3.2B. In fiscal 2025 capital spending exceeded operating cash flow by $2.1B. At June 30, 2026 it held $1.7B in cash against $591M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 31, 2026.
What Moderna, Inc. does
Moderna, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker MRNA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.9B | -$2.8B | -$7.26 | -$2.1B |
| 2024 | $3.2B | -$3.6B | -$9.28 | -$4.1B |
| 2023 | $6.8B | -$4.7B | -$12.33 | -$3.8B |
| 2022 | $19.3B | $8.4B | $20.12 | $4.6B |
| 2021 | $18.5B | $12.2B | $28.29 | $13.3B |
| 2020 | $803M | -$747M | -$1.96 | $2B |
Latest SEC filings
What Moderna, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 1, 2026
- August 12, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- July 31, 2026Quarterly report 10-Q · period to June 30, 2026
- July 31, 2026
- July 24, 2026Passive stake changed SCHEDULE 13G/A
- July 8, 2026
- May 11, 2026
- May 1, 2026Quarterly report 10-Q · period to March 31, 2026
- May 1, 2026
Questions about MRNA
What does Moderna, Inc. do?
Moderna, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker MRNA.
Is Moderna, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $3.2B on revenue of $2.2B.
How much revenue does Moderna, Inc. make?
Over the twelve months to June 30, 2026 Moderna, Inc. reported revenue of $2.2B. That is 27.6% less than a year earlier.
When did Moderna, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 31, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 16, 2026.
Similar companies
Follow MRNA
Get an email when Moderna, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow MRNA: get an email when it filesWhere the numbers come from
Financial figures are the values Moderna, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.